PATIENTS & FAMILIES

Patients and their families are at the core of everything we do. Tern Therapeutics is committed to integrity, empathy, urgency, innovation, and determination as we work in partnership with patient communities at every stage of development to deliver treatments to those living around the world with rare diseases.
URGENCY
INTEGRITY
EMPATHY
DETERMINATION
INNOVATION

The TTX-381 clinical trial is currently underway at Great Ormond Street Hospital in London.
Learn more at clinicaltrials.gov.
For further information, please contact us at patientadvocacy@terntx.com.
Expanded Access
Tern Therapeutics is driven to deliver transformative treatments with urgency to those living around the world with rare diseases. Patients and their families are at the core of everything we do.
OUR COMMITMENT TO CLINICAL RESEARCH
We are committed to a rigorous clinical development process to evaluate the safety and efficacy of our investigational gene therapy candidates through clinical trials, while minimizing safety risks to patients. We believe that it is through clinical trials and regulatory approval that we can ultimately ensure safe and timely access to our medicines for as many patients as possible suffering from these devastating diseases.
For information about our clinical trials, please visit clinicaltrials.gov or contact our Patient Advocacy team at patientadvocacy@terntx.com. You may also have a member of your medical care team contact us at medinfo@terntx.com.
EXPANDED ACCESS POLICY
We understand that there may be circumstances under which patients or caregivers may request treatment with our investigative therapies before they have been approved by regulatory agencies and outside of a clinical trial setting. This is sometimes called “expanded access,” “compassionate use,” “early access,” “right to try,” or a “named patient program.” We use the term “expanded access” to capture all of these.
After careful consideration, Tern Therapeutics has decided that the best way for patients to access our investigational therapies at this time is through clinical trial participation. As a result, we will not offer expanded access at this time.
Any requests for expanded access will be referred to study investigators to determine a patient’s eligibility for one of our ongoing clinical studies. If a patient does not qualify for one of our ongoing clinical studies, Tern Therapeutics will direct such patients, caregivers, and/or their treating physician to patient organizations and/or medical professionals who may be able to identify other clinical studies or approved treatment options.
As provided by the 21st Century Cures Act, Tern Therapeutics reserves the right to revise this policy at any time.
Additional Resources
What's in a Name?
To learn more about the Arctic tern, our company's namesake, we invite you to visit “To the Ends of the Earth” at National Geographic Education.